Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Pamela Pritchard

Nurse Practitioner, Acute Care Fairmont, WV Nurse Practitioner

NPI 1912398843 CMS profile 11134268

1322 Locust Ave, Fairmont, WV 26554

Open in the dashboard

General payments

$271

16 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Pritchard of Fairmont, WV is reported in the CMS Open Payments database as having received $271 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37 2
2023 General $63 3
2022 General $147 10
2021 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Pritchard
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Pamela Pritchard were reported at $37. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Pamela Pritchard Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $24 $123 $38–$327 $132
2022 $147 $130 $44–$369 $149
2023 $63 $144 $49–$410 $160
2024 $0 $146 $48–$433 $164
2025 $37 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $56 3 payments
  2. AbbVie, Inc. $43 2 payments
  3. LeMaitre Vascular, Inc. $28 2 payments
  4. Paratek Pharmaceuticals, Inc. $28 2 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $24 1 payment
  6. Verona Pharma, Inc. $22 1 payment
  7. Esperion Therapeutics, Inc. $15 1 payment
  8. Hologic, LLC $15 1 payment
  9. Bioventus LLC $14 1 payment
  10. Smith+Nephew, Inc. $13 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $271 16 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $56 3 payments
  2. LYNPARZA $56 3 payments
  3. DALVANCE $43 2 payments
  4. ARTEGRAFT VASCULAR GRAFT $28 2 payments
  5. NUZYRA $28 2 payments
  6. GATTEX $24 1 payment
  7. Ohtuvayre $22 1 payment
  8. NEXLETOL $15 1 payment
  9. TRIDENT SPECIMEN RADIOGRAPHY SYSTEM $15 1 payment
  10. Localizer $15 1 payment
  11. Other $53 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,677

Median for Nurse Practitioner: 389

Drug cost

$44,136

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 69 $19,149
Januvia Sitagliptin Phosphate Brand 15 $4,551
Ertapenem Ertapenem Sodium Brand 11 $3,202
Lantus Insulin Glargine,hum.Rec.Anlog Brand 31 $2,262
Potassium Chloride Generic 89 $941
Pantoprazole Sodium Generic 52 $936
Atorvastatin Calcium Generic 109 $925
Levothyroxine Sodium Generic 114 $913
Metoprolol Succinate Generic 72 $627
Nystatin-Triamcinolone Nystatin/Triamcinolone Acet Brand 13 $619

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$38,720

Medicare's payments for the services billed

Medicare patients

64

Average age 83

Services billed

531

51 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Alzheimer's or dementia 59%
Diabetes 44%
Depression 44%
Chronic kidney disease 39%
Atrial fibrillation 38%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record